The U.S. Food and Drug Administration has approved AstraZeneca’s (NASDAQ:AZN) Saphnelo (anifrolumab) for self-administration via a once-weekly autoinjector, the Saphnelo Pen.
This new subcutaneous delivery method is indicated for adult patients with moderate to severe systemic lupus erythematosus (SLE) receiving standard therapy, providing a portable alternative to the previously available intravenous infusion.
The regulatory green light follows successful results from the Phase III TULIP-SC trial, published in Arthritis & Rheumatology in January 2026.
The study demonstrated that subcutaneous administration achieved a statistically significant and clinically meaningful reduction in disease activity compared to a placebo.
Crucially, the safety profile of the autoinjector remained consistent with the established intravenous clinical profile, which has already been used to treat over 40,000 patients globally.
The shift toward self-administration addresses a significant need for convenience in the lupus community, particularly as the disease disproportionately affects young women and minority populations.
By allowing for home-based care, the Saphnelo Pen aligns with updated clinical guidelines that prioritize reaching low disease activity while minimizing the long-term use of oral corticosteroids.
From a financial perspective, the approval strengthens AstraZeneca’s immunology portfolio.
Under a 2025 update to an existing licensing agreement with Medarex (now owned by Bristol-Myers Squibb), AstraZeneca will pay a mid-teens royalty on U.S. sales of the drug.
Subcutaneous Saphnelo is already approved in the EU and Japan, with further regulatory reviews ongoing as AstraZeneca seeks to transition its clinical successes into a more accessible, patient-centric format.